---
schema_version: "secwatch.filing_event.v1"
accession: "0000064803-24-000009"
form_type: "8-K"
ticker: "CVS"
cik: "0000064803"
company_name: "CVS HEALTH Corp"
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T04:21:54.969485+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# CVS Health reiterates FY2024 guidance: GAAP EPS ≥$7.06, adjusted ≥$8.30

## Summary
- Reaffirmed FY2024 GAAP diluted EPS guidance of at least $7.06.
- Reaffirmed FY2024 Adjusted EPS guidance of at least $8.30.
- Reaffirmed FY2024 cash flow from operations guidance of at least $12.0 billion.
- CFO Tom Cowhey to discuss business trends at March 5 webcast.
- Guidance unchanged; no new financial information provided.

## SEC filing metadata
- accession: 0000064803-24-000009
- form_type: 8-K
- ticker: CVS
- cik: 0000064803
- company_name: CVS HEALTH Corp
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/64803/000006480324000009/0000064803-24-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/64803/000006480324000009/cvs-20240305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000064803-24-000009
- JSON: https://secwatch.observer/filing/0000064803-24-000009.json
- Plain text: https://secwatch.observer/filing/0000064803-24-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.